Treatment options are limited for patients with relapsed/refractory MCL, particularly those who have experienced progression on a previous BTK inhibitor, Phillips begins. Currently available options include CAR T-cell therapy, such as brexucabtagene autoleucel (brexu-cel; Tecartus), and the non-covalent BTK inhibitor pirtobrutinib (Jaypirca), he explains. Moreover, this drug class is associated with high costs and toxicities, making it less suitable for all patients, Phillips emphasizes. Long-term data for pirtobrutinib do not strongly support its durability in relapsed/refractory MCL, especially for patients who progressed on a BTK inhibitor, he adds. The goal is to enroll a total of 182 patients, Phillips notes, adding that investigators are aiming for rapid accrual and an early readout, Phillips notes.

Source: Wall Street Journal January 12, 2024 22:43 UTC